Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00258882 · ClinicalTrials.gov registry record
Descriptive, Post-marketing, Passive Surveillance Safety Study of ADACEL™ Vaccine
A clinical trial of Pertussis, sponsored by Sanofi Pasteur, a Sanofi Company.
- Completed
- Registry status
- 327,293
- Enrollment target
- 3
- Study locations
NCT00258882 is a study of Pertussis that has completed, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 327,293 participants, above the 15,552-participant average among 14 other Pertussis trials with a reported enrollment target (2005% higher). The trial reports 3 study locations across 3 states.
The verdict
NCT00258882, a study of Pertussis, has completed, sponsored by Sanofi Pasteur, a Sanofi Company.
- COMPLETED
- Registry status
- 327,293 participants
- Enrollment target
- 3
- Study locations
Study Summary
To further characterize the vaccine safety profile and to identify any signals of potentially vaccine-related adverse events (AEs) not detected during pre-licensure studies.
Conditions Studied
Interventions
- BIOLOGICAL Tetanus Toxoid, acellular pertussis, diphtheria toxoid
Study Locations (3)
California
- - Oakland
Colorado
- - Aurora
Oregon
- - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 327,293 participants |
| Start Date | 2006-01 |
| Est. Completion | 2012-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00258882
The ClinicalTrials.gov registry entry for NCT00258882 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 327,293 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 15,552-participant average among 14 other Pertussis trials with a reported enrollment target (2005% higher). The listed sponsor is Sanofi Pasteur, a Sanofi Company, which has 153 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pertussis appearing as the primary indexed condition, and to 1 intervention - of which Tetanus Toxoid, acellular pertussis, diphtheria toxoid is the first listed.
NCT00258882 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Colorado, Oregon.
Frequently Asked Questions
What is clinical trial NCT00258882 about?
NCT00258882 is a clinical study titled "Descriptive, Post-marketing, Passive Surveillance Safety Study of ADACEL™ Vaccine". To further characterize the vaccine safety profile and to identify any signals of potentially vaccine-related adverse events (AEs) not detected during pre-licensure studies.
What is the current status of trial NCT00258882?
This trial is currently completed. The enrollment target is 327,293 participants. The study started on 2006-01. Estimated completion is 2012-12.
What conditions does trial NCT00258882 study?
This clinical trial studies the following conditions: Pertussis.
What interventions are being tested in trial NCT00258882?
The interventions under investigation include: Tetanus Toxoid, acellular pertussis, diphtheria toxoid (BIOLOGICAL).
Who is sponsoring clinical trial NCT00258882?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00258882 being conducted?
This trial has 3 study locations across California, Colorado, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pertussis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pentavalent DTaP-Hep B-IPV
COMPLETED · Phase 2
-
Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX®
COMPLETED · Phase 4
-
Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents
COMPLETED · Phase 4
-
Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™
COMPLETED · Phase 4
-
Study on the Safety and Immunogenicity of Boostrix Vaccine in Pregnant Malian Women and Their Infants
COMPLETED · Phase 2
-
Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.